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Given the high prevalence of cognitive impairment in Parkinson’s disease (PD), cognitive
screening is important in clinical practice. The Montreal Cognitive Assessment (MoCA) is a
frequently used screening test in PD to detect mild cognitive impairment (PD-MCI) and Par-
kinson’s disease dementia (PD-D). However, the proportion in which the subtests are repre-
sented in the MoCA total score does not seem reasonable. We present the development
and preliminary evaluation of an empirically based alternative scoring system of the MoCA
which aims at increasing the overall diagnostic accuracy.
Methods
In study 1, the MoCA was administered to 40 patients with PD without cognitive impairment
(PD-N), PD-MCI, or PD-D, as defined by a comprehensive neuropsychological test battery.
The new MoCA scoring algorithm was developed by defining Areas under the Curve (AUC)
for MoCA subtests in a Receiver Operating Characteristic (ROC) and by weighting the sub-
tests according to their sensitivities and specificities. In study 2, an independent sample of
24 PD patients (PD-N, PD-MCI, or PD-D) was tested with the MoCA. In both studies, diag-
nostic accuracy of the original and the new scoring procedure was calculated.
Results
Diagnostic accuracy increased with the new MoCA scoring algorithm. In study 1, the sensi-
tivity to detect cognitive impairment increased from 62.5% to 92%, while specificity
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decreased only slightly from 77.7% to 73%; in study 2, sensitivity increased from 68.8% to
81.3%, while specificity stayed stable at 75%.
Conclusion
This pilot study demonstrates that the sensitivity of the MoCA can be enhanced substan-
tially by an empirically based weighting procedure and that the proposed scoring algorithm
may serve the MoCA’s actual purpose as a screening tool in the detection of cognitive dys-
function in PD patients better than the original scoring of the MoCA. Further research with
larger sample sizes is necessary to establish efficacy of the alternate scoring system.
Introduction
Cognitive dysfunction is frequent in patients with Parkinson’s disease (PD). They are highly
relevant, as they limit the patients’ quality of life, increase caregiver burden [1], are an impor-
tant indication for institutionalization [2], and are related to disease prognosis [3] and mortal-
ity [4,5]. Already 20% of unmedicated de-novo PD patients have cognitive symptoms [6,7].
Mild Cognitive Impairment (MCI) affects about 27% of non-demented PD patients (PD-MCI)
[8], and about 30% of PD patients develop Parkinson’s disease dementia (PD-D) [9]. Thus, for
an optimal management of PD patients, early detection of cognitive symptoms in clinical prac-
tice is of utmost importance.
Cognitive screening tests are time-economic and efficient tools to detect cognitive symp-
toms and dementia [10] and can represent the initial step in a process of clinical decision-mak-
ing. The Montreal Cognitive Assessment (MoCA) [11] is a widely used tool that has also been
recognized to be efficient in detecting cognitive symptoms in PD patients [12–14]. Its sensitiv-
ity has consistently been proven to be higher than that of the Mini Mental State Examination
(MMSE) [15,16], especially for detecting milder cognitive symptoms [17,18]. The MoCA has
also been shown to be suitable to differentiate PD patients with different cognitive states (with
no cognitive impairment, mild cognitive impairment, or dementia) from healthy controls [13].
The combination of subtests can be regarded as a strength of the MoCA, as a broad range of
cognitive domains is covered and assessed with established test paradigms, including very sen-
sitive tasks for the evaluation of executive dysfunction [19] which is of special relevance in PD
[20,21]. However, it is striking that its scoring procedure is not based on the discriminant
power of the individual subtests. Rather, it is based on the raw scores of the subtests which are
simply summed up to a total score of 30 points. This leads to the fact that, for example, the ver-
bal fluency task, although known to be very sensitive in PD patients [22], receives only 1 point
(and thus represents only 1/30th of the total score), while, for example, the language items
“naming”–a function that is by far less frequently affected in PD—constitute 3/30th of the total
score.
Previous research already indicated that the MoCA subtests may differ substantially in their
respective diagnostic values. In a study by Ohta et al. [23] including 304 PD patients, three
MoCA subtests did not discriminate between patients with low, middle, and high MoCA total
scores: The target tapping task, the naming task, and the orientation task. Even though no com-
prehensive neuropsychological evaluation was used to establish the cognitive state of the partic-
ipants, this suggests that these items did not add additional information to the determination
of the overall cognitive status of the PD patients. In a study [24] focusing on patients with MCI
and Alzheimer’s disease (AD), it was shown that only the learning, digit span, serial
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subtraction, repetition, verbal fluency, abstraction and memory task discriminated between
healthy control participants and the MCI group, whereas only the clock drawing task, rhino
naming, memory, and orientation tasks discriminated between the MCI and the AD group.
Although this study did not include PD patients, it provides further evidence that the MoCA
subtests differ considerably in their diagnostic accuracy. Thus, the question arises as to whether
an alternative scoring procedure reflecting the subtests’ ability in detecting cognitive dysfunc-
tion in PD would increase the instrument’s sensitivity. In fact, scoring procedures of cognitive
screening instruments which consider the subtests’ individual discriminant validity and
include corresponding weighting of subtests have been proposed [25].
Thus, the aim of this pilot study was to develop an initial version of a new scoring procedure
for the MoCA which considers the subtests’ power to detect cognitive symptoms in PD, and to
test whether it improves the ability to discriminate PD patients without cognitive impairment
(PD-N) from patients with PD-MCI and PD-D. For this purpose, a scoring algorithm was
developed and tested in a first sample of PD patients (study 1). Study 2 evaluated the new scor-
ing algorithm on an independent sample of PD patients. In both study samples, the tool’s diag-
nostic accuracy of the “classical”MoCA and the MoCA with the newly developed scoring
system was calculated and compared.
Methods
Recruitment of patients and definition of diagnostic groups (PD-N,
PD-MCI, PD-D)
In both study 1 and study 2, data from neuropsychological routine testing (for a detailed
description please see section “neuropsychological examination” below) of consecutively
recruited inpatients with idiopathic PD according to the UK Parkinson’s Disease Society
Brain Bank clinical diagnostic criteria [26] seen at the Parkinson’s Disease and Movement
Disorders Unit of the Department of Neurology, University Hospital of Cologne, Germany,
were included. No limitations with regard to gender, age, race, or disease duration were
applied, but only data from patients with German as mother tongue and with no neurological
diseases other than PD were included. Exclusion criteria were severe cognitive dysfunction
associated with aphasia as well as an overall physical health state which made it impossible to
conduct the neuropsychological tests.
Depressive symptoms were assessed with the Geriatric Depression Scale 15 (GDS-15) [27].
Motor symptoms were examined by experienced neurologists with the Unified Parkinson’s
Disease Rating Scale (UPDRS) [28]. Total dopaminergic treatment was calculated as the levo-
dopa equivalent daily dose (LEDD) according to the following formula: 1 mg pergolide = 1 mg
lisuride = 1 mg pramipexole = 2 mg cabergoline = 5 mg ropinirole = 10 mg bromocriptine = 10
mg apomorphine = 20 mg dihydroergocryptine = 100 mg levodopa proposed by Tomlinson
et al. [29].
Patients were classified as PD patients with no cognitive dysfunction (PD-N) or as PD-MCI
or PD-D patients according to the Movement Disorder Society (MDS) Task Force Level II cri-
teria for PD-MCI [8] and MDS criteria for PD-D [30], respectively. More specifically, PD-MCI
criteria included 1) a diagnosis of PD according to Queen Square Brain Bank criteria [26], 2)
cognitive complaints reported by the patient or observed by the clinician, 3) deficits on at least
two neuropsychological tests, either two impaired tests in one domain, or one impaired test in
two different domains, and 4) no dysfunction of activities of daily living (ADL) because of cog-
nitive impairment. To assess the latter point, subjective reports of cognitive decline and ADL
impairments due to cognitive dysfunction were obtained during a semi-structured interview
preceding the neuropsychological examination. Patients were asked to indicate whether they
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had noted any meaningful change over the course of their illness in their ability to remember
things, to pay attention, to plan and execute complex activities, their visuospatial functions, or
their language functions. If subjective impairments were reported, patients were asked to evalu-
ate whether these deficits caused any ADL impairment, independent of the impairment ascrib-
able to the motor symptoms. MDS PD-D criteria [30] included 1) a diagnosis of PD according
to Queen Square Brain Bank criteria, 2) cognitive deficits in at least two of the five cognitive
domains named above as evidenced by deficits in at least one test for a domain, and 3) ADL
impairments that are not primarily attributable to motor symptoms associated with PD,
assessed as described above. The ethics commission of the Faculty of Medicine of the Univer-
sity Hospital of Cologne advised that no formal approval was required as the study only
involved retrospective analysis of data collected during standard care and no identifying infor-
mation is reported.
Neuropsychological examination
The neuropsychological examination was conducted by an experienced neuropsychologist (sf)
during the patients’ on-phase after medication and, in case of deep brain stimulation of the
subthalamic nucleus (STN-DBS), with the deep brain stimulator switched on. In addition to
the MoCA, the cognitive state was measured using the MMSE [15,16]. Both screening proce-
dures were not used for classification of PD-N, PD-MCI, and PD-D. In accordance with MDS
task force criteria for PD-MCI and PD-D, each cognitive domain was assessed with two neuro-
psychological tests: Verbal Memory was measured with the word list memory and the word list
recall task of the Consortium to Establish a Registry for Alzheimer's Disease test battery
(CERAD) [31]. Executive functions were assessed with the Trail Making Test (TMT) B/A Index
and the semantic verbal fluency task (animal naming) of the CERAD. Attention was tested
with the Wechsler Memory Scale—Revised (WMS-R) [32] block span task and the WMS-R
digit span backward task. Visuospatial functions were measured with the mental rotation test
of the Achievement Testing System 50+ (LPS 50+) [33], and the CERAD constructional praxis
task. Finally, language was tested with the CERAD 15-item Boston Naming Test and the audi-
tory comprehension subtest of the Aphasia Check List (ACL) [34]. For the CERAD subtests, a
score of 1.128 standard deviations below the normative data was considered to represent a
deficit, as recommended in the German CERAD test manual [35]. This cutoff score corre-
sponds to a percentile rank of 10 for the WMS-R subtests and the mental rotation subtest of
the LPS 50+. Age-adjusted scores were used for all tests. Furthermore, CERAD scores were also
gender- and education-corrected.
Statistical analyses
All data were completely anonymized prior to analysis (ek). They were analyzed using IBM
SPSS Statistics 22. In both studies, possible differences between demographic, clinical and
neuropsychological test data of the three diagnostic patient groups were examined by means of
a Univariate Between-Subjects ANOVA. Post-hoc comparisons for the neuropsychological
variables were made using Bonferroni correction. Results of the Shapiro-Wilk test of normality
showed that not all clinical and sociodemographic variables were normally distributed. For
these variables, the non-parametric equivalent Kruskal Wallis-Test and the Mann-Whitney U
test for pairwise comparisons (with Bonferroni adjusted alpha-levels for the neuropsychologi-
cal test data) were used. The Fisher’s Exact test was used for dichotomous variables. A one-way
Between-Subjects ANOVA was conducted to compare MoCA Total scores between impaired
(PD-MCI and PD-D) and unimpaired patients (PD-N). For the comparison of neuropsycho-
logical test data and of the original and weighted MoCA scores, the effect size r was computed.
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For non-parametric tests, scores were transformed into ranks, partial eta-squared was com-
puted by running an ANOVA on the ranked scores, and finally the square root was taken to
obtain r. In both studies, it was tested whether the new weighting was successful in increasing
the overall discriminating power of the MoCA. For this purpose, the diagnostic accuracy of the
original and the new weighted total score were compared by means of their sensitivity and
specificity as well as the Youden’s Index [36] [= sensitivity–(1 –specificity)] which is a fre-
quently used summary measure of the ROC curve that captures the performance of a diagnos-
tic test with a single numerical value. For a test with poor diagnostic accuracy, Youden's index
equals 0, and in a perfect test Youden's index equals 1. Furthermore, the positive predictive
value and the negative predictive value of the original and the weighted MoCA score were cal-
culated for study 1 and 2. The AUC values of the original and the weighted MoCA were com-
pared using the method of de Long et al. [37]
Weighting and new scoring procedure of the MoCA. In the current analysis, the AUCs
of the MoCA were calculated as a measure of the discriminating power of the weighted MoCA
algorithm, since the MoCA only proposes one cutoff score to discriminate cognitively unim-
paired versus cognitively impaired patients, without distinction between MCI and dementia
[11]. Therefore, in the determination of sensitivity and specificity, PD-MCI and PD-D patients
were analyzed together as a group of patients with cognitive impairment. Fig 1 shows the devel-
opment process of the new weighting system.
Fig 1. Presentation of the development of the newMoCAweighting.
doi:10.1371/journal.pone.0159318.g001
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The weights of the MoCA subtests in the original version, the AUCs for each subtest, new
weights and new maximum points are displayed in Table 1. Table 2 shows the scoring algo-
rithm for assigning raw scores to weighted points for each subtest. In S1 Fig, a case report of a
re-scored MoCA is shown.
Results
Study 1
Study sample. Forty PD patients were consecutively recruited between April and June
2013, 15 of which had no cognitive impairment (PD-N), 14 had PD-MCI, and 11 were classi-
fied as having PD-D. Mean age was 65.4 years (SD 9.8; range 46 to 86 years), mean education
(school and higher education) was 14.4 years (SD 3.8, range 7 to 21 years), and 30% (n = 12) of
the sample was female. Eleven participants scored above four points on the GDS-15 suggesting
depressive symptoms. Mean UPDRS score was 24 (SD 12.8), and the mean LEDD in the sam-
ple was 460.4 (SD 410.1). Nineteen patients had undergone a STN-DBS. Sociodemographic
and clinical data of the three diagnostic groups are shown in Table 3. All neuropsychological
test results and group comparisons are shown in the S1 Table.
Testing the new scoring algorithm of the MoCA in the original sample—Comparison of
original and weighted total scores of the MoCA. The original and weighted MoCA total
scores are displayed in Fig 2. On a descriptive level, all weightedMoCA total scores, especially
those in the PD-MCI and the PD-D group, were lower than the original total scores. Both the orig-
inal and the weightedMoCA total scores differed significantly between the impaired PD patients
(PD-MCI and PD-D together) and the unimpaired PD patients (PD-N; F1,38 = 8.32, p = .006, r =
.42 and F1,38 = 9.82, p = .003, r = .45, respectively). After excluding PD-D patients, the difference in
the MoCA total score between the PD-N and the PD-MCI group was still significant in both ver-
sions (F1,27 = 5.47, p = .027, r = .41 and F1,27 = 5.54, p = .026, r = .41, respectively). As expected,
also scores between the PD-N and the PD-D group were significant (F1,24 = 8.71, p = .007, r = .52
and F1,24 = 9.48, p = .005, r = .53, respectively). For the original and weighted scoring, no signifi-
cant difference was found between the total scores of PD-MCI and the PD-D patients (F1,23 = 0.98,
p = .33, r = .20 and F1,31 = 1.12, p = .29, r = .22, respectively).
Table 1. AUCs of the MoCA subtests in study 1, original and weighted subtest points.
Domain* Subtests Original Points % Original Points AUC Weighted Points %Weighted Points
Visuospatial and executive functions Alternating Trail Making 1 3 0.74 4 13
Cube copy 1 3 0.67 3 10
Clock-drawing 3 10 0.83 5 17
Naming Animal Naming 3 10 0.56 1 4
Attention Digit Span 2 7 0.59 1 4
Target tapping 1 3 0.58 1 4
Serial subtraction 3 10 0.51 1 4
Language Repetition 2 7 0.66 3 9
Verbal ﬂuency 1 3 0.62 3 9
Abstraction Abstraction 2 7 0.52 1 4
Memory Learning 0 0 0.62 3 9
Memory 5 17 0.61 3 9
Orientation Orientation 6 20 0.56 1 4
* as assigned by the authors of the MoCA [11].
doi:10.1371/journal.pone.0159318.t001
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Table 2. Conversion table for scoring of the MoCA subtests.
MoCA Subtest Original Points New Points
Visuospatial and executive functions Alternating Trail Making 0 0
1 4










Attention Digit Span 0 0
1 0
2 1
Target tapping 0 0
1 1




Language Repetition 0 0
1 2
2 3
Verbal ﬂuency 0 0 to 3 words: 0
1 4 to 7 words: 1
8 to 10 words: 2
> 10 words: 3
Abstraction Abstraction 0 0
1 0
2 1
Memory Learning 0 3 to 5 words: 1
6 to 8 words: 2
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Discriminating patient groups with the original and the weighted MoCA total scores.
Sensitivities and specificities of the original and the weighted MoCA score were compared
using the original cutoff score of 26/30 for cognitive impairment. Analyses showed that the
original MoCA total score discriminated patients with preserved cognition (PD-N) from those
with cognitive impairment (PD-MCI and PD-D) with a sensitivity of 62.5% and a specificity of
Table 3. Demographic and clinical characteristics of all diagnostic groups in study 1.




p-value (PD-N vs. PD-cognitively
impaired)
(n = 15) (n = 14) (n = 11) (PD-MCI& PD-D;
n = 25)
Male/female a n (%) 14 /1 6/8 8/3 .012 b 14/11 .015
Age (years) c Mean (SD) 63.5 (8.8) 64.2 (9.5) 69.4 (11.1) .285 66.5 (10.4) .363
Median
(IQR)d
65 (55–68) 61.5 (56.5–
73,25)
71 (61–76) 69 (58.5–74.5)
Education (years) d Mean (SD) 15.2 (4.1) 13.6 (3.3) 14.2 (4.0) 13.8 (3.5)
Median
(IQR)
16 (11–18) 13 (11–15.75) 13 (11–18) .662 13 (11–18) .455
PD duration c Mean (SD) 8.4 (4.7) 10.5 ± 5.1 10.6 ± 7.0 .515 10.5 (5.9) .246
Median
(IQR)
10 (5–12) 10 (7.5–15) 10 (8–14) 10 (8–15)
Age at diagnosis c Mean (SD) 55.1 (8.9) 52.9(11.3) 58.7 ± 10.8 .385 55.5 (11.2) .906
Median
(IQR)
52.0 (51–62) 54 (46–62.5) 60 (49–71) 55.5 (47.25–64.5)





20 (16–34) 31 (20–35) 30 (16.75–34.25)
History of DBS a (% yes) 60% 43% 36% .526 40% .333





17 (5–34) 25 (5–39) 40 (16–76) .652 26 (11.25–47.25) .497










GDS-15 score d Mean (SD) 2 (1.7) 3.9 (2.6) 5.9 (3.4) 4.6 (3.0)
Median
(IQR)
2 (0–3) 4 (1.75–6) 4 (4–9) .01e 4 (2–6.25) .005
MMSE d Mean (SD) 29.0 (0.9) 28.3 (1.3) 27.1 (1.8) 27.9 (1.5)
Median
(IQR)
29 (28.5–30) 29 (27.5–29) 28 (25–29) .029 f 28.5 (26.25–29) .036
SD, Standard deviation; IQR, Interquartile range; LEDD, total daily levodopa equivalent dose.
a Fisher`s Exact test was used for dichotomous variables.
b Pairwise comparisons showed that the male/female ratio was higher in PD-MCI compared to PD-N; PD-N = PD-D; PD-MCI = PD-D.
c A univariate Between-Subjects ANOVA with post-hoc comparisons was used for variables that were normally distributed. P-values are shown for the mean.
Median and interquartile range are also reported for comparison purposes.
d The Kruskal-Wallis test was used for variables that were not normally distributed. P-values are shown for the median. Groups were compared using the
Mann-Whitney U test. Means and standard deviations are also reported for comparison purposes.
e Pairwise comparisons showed that PD-N = PD-MCI = PD-D; PD-N<PD-D.
f Pairwise comparisons showed that PD-N = PD-MCI = PD-D; PD-N>PD-D.
doi:10.1371/journal.pone.0159318.t003
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77.7%, while the weighted MoCA total score had an increased sensitivity of 92% and a slightly
reduced specificity of 73%. These data correspond to a Youden’s Index of the original and the
weighted MoCA total scores of 0.41 and 0.65, respectively. With regard to detection of
PD-MCI in contrast to PD-N patients, the original MoCA total score had a sensitivity of 55.5%
and a specificity of 83.3%, while the weighted MoCA had a much higher sensitivity of 92.9 and
a reduced specificity of 72%. The corresponding Youden’s Indices were 0.33 and 0.64, respec-
tively. Finally, with regard to detection of dementia (PD-N versus PD-D), the original MoCA
total score had a sensitivity of 72.8% and a specificity of 83.3%, while the weighted MoCA had
a higher sensitivity of 90.9% and a slightly lower specificity of 79%. These data correspond to a
Youden’s Index of 0.56 and 0.69, respectively. The PPV of the original MoCA for the detection
of any cognitive disorder was 75, and the NPV was 52.6. The PPV of the new MoCA increased
to 88.5%, and the NPV increased to 77.8%.
Study 2
Study sample. Twenty-four PD patients were recruited consecutively between November
2014 and February 2015–8 with PD-N, 10 with PD-MCI, and 6 with PD-D, and were included
in study 2. Mean age was 65.1 years (SD 10.4; range 46 to 78 years), mean education was 12.8
years (SD 3.4, range 7 to 20 years), and 21% (n = 5) of the sample was female. Eleven partici-
pants scored above four points on the GDS-15 indicating at least mild depressive symptoms.
Mean UPDRS score was 20.2 (SD 6.2), and the mean LEDD in the sample was 613.8 (SD
354.8). Sixteen patients had undergone STN-DBS. Sociodemographic and clinical data of the
three groups are shown in Table 4. Results and comparisons of neuropsychological data of the
three groups are shown in the S2 Table.
Testing the new scoring algorithm of the MoCA in an independent study sample—Com-
parison of original and weighted total scores of the MoCA. The original and weighted
MoCA total scores of study sample 2 are displayed in Fig 3. As in study 1, all weighted MoCA
total scores were lower than the original total scores. The original as well as the weighted MoCA
scores differed significantly between the impaired PD patients (PD-MCI and PD-D together)
Fig 2. MoCA original and weighted scores by diagnostic group in study 1.
doi:10.1371/journal.pone.0159318.g002
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and the unimpaired PD patients (PD-N; F1,22 = 9.84, p = .005, r = .56 and F1,22 = 5.49, p = .02,
r = .48, respectively). After excluding PD-D patients, the difference in the MoCA total score
between the PD-N and the PD-MCI group was still significant for both scoring systems (F1,16 =
8.15, p = .01, r = .58 and F1,16 = 5.29, p = .03, r = .50, respectively). Scores between the PD-N
and the PD-D group were also significant (F1,12 = 9.75, p = .009, r = .67 and F1,12 = 5.67, p = .035,
r = .57, respectively). For both the original and the weighted MoCA, no significant difference
Table 4. Demographic and clinical characteristics of all diagnostic groups in study 2.




p-value (PD-N vs. PD-
cognitively impaired)
(n = 8) (n = 10) (n = 6) (PD-MCI& PD-D;
n = 16)
Male/female a n (%) 7/1 9/1 3/3 .161 12/4 .613
Age (years) b Mean (SD) 66.5 (6.7) 65.0 (10.2) 63.3 (15.5) .864 64.4 (12.0) .647
Median
(IQR)





Education (years) b Mean (SD) 14.0 (4.6) 12.9 (2.3) 11.0 (1.6) .277 12.2 (2.7)
Median
(IQR)
15 (9.8–18.0) 12 (12.0–13.0) 12 (9.0–12.0) 12 (12–12) .383
PD duration b Mean (SD) 7.6 (4.5) 6.4 (3.5) 6.5 (4.7) .815 6.4 (3.9) .519
Median
(IQR)
8 (3.3–11.3) 6.5 (4.2–9.0) 6 (4.0–10.3) 6.5 (2.5–9)
Age at diagnosis b Mean (SD) 59.0 (8.6) 58.7 (12.75) 57.3 (14.3) .964 58.19 (12.9) .874
Median
(IQR)





UPDRS III b Mean (SD) 22.3 (9.6) 18.6 (3.3) 20.0 (6.0) .894 19.1 (4.1) .435
Median
(IQR)
17.5 (10–17.5) 20.0 (16.5–22) 20.0 (14–20) 19.0 (15.25–22.0)
History of DBS a (% yes) 50% 30% 17% d .556 25% .363
Interval since DBS
Implantation(months)c
Mean (SD) 13.3 (7.9) 21.0 (7.9) 20.0 d 20.8 (6.5)
Median
(IQR)
13 (5–21) 18 (15–18) 20.0 d .419 19.0 (15.75–27.5) .200











GDS-15 score b Mean (SD) 2.6 (1.9) 4.9 (3.6) 7.7 (4.9) .032 e 5.9 (3.9) .034
Median
(IQR)
3 (0.5–4.0) 5.0 (2.3–7.0) 9.5 (2.8–11) 5 (3–10)
MMSE c Mean (SD) 29.25 (0.46) 28.0 (1.56) 26.0 (2.53) 27.25 (2.15)
Median
(IQR)
29 (29.0–29.75) 28.5 (2) 26 (23.8–
27.8)
0.021 f 27.5 (25.25–29.0) .019
SD, Standard deviation; IQR, Interquartile range; LEDD, total daily levodopa equivalent dose.
a Fisher`s Exact test was used for dichotomous variables.
b A univariate Between-Subjects ANOVA with post-hoc comparisons was used for variables that were normally distributed. P-values are shown for the
mean. Median and interquartile range are also reported for comparison purposes.
c The Kruskal-Wallis test was used for variables that were not normally distributed. Groups were compared using the Mann-Whitney U test. P-values are
shown for the median. Means and standard deviations are also reported for comparison purposes.
d Only 1 patient in the PD-D group had a history of DBS.
e Pairwise comparisons showed that PD-N = PD-MCI = PD-D; PD<PD-D.
f Pairwise comparisons showed that PD-N = PD-MCI = PD-D; PD-N>PD-D.
doi:10.1371/journal.pone.0159318.t004
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was found between the total scores of the PD-MCI and the PD-D patients (F1,14 = 2.14, p = .16,
r = .36 and F1,14 = 1.77, p = .21, r = .33, respectively).
Discriminating patient groups with the original and the weighted MoCA total scores.
The AUC values of the original and the new MoCA total score were not significantly different
(0.87 and 0.83, respectively; p = 125). However, considering the individual diagnostic parame-
ters, results indicate that when retaining the original cutoff score of 26/30 points, the original
MoCA discriminated patients with normal cognition from those with impaired cognition with
a sensitivity of 68.8% and a specificity of 75% whereas the new weighted total score reached a
sensitivity of 81.3%, while the specificity remained unchanged with 75%. These values corre-
spond to a Youden’s Index of 0.43 and 0.56, respectively. The original MoCA score had a PPV
of 84.6% and a NPV of 54.6%, while the score based on the new algorithm had a PPV of 86.7%
and a NPV of 66.7%.
Discussion
The present study was designed to propose a new scoring algorithm for the cognitive screening
instrument MoCA in which the tool’s subtests are weighted according to their sensitivity and
specificity and to preliminarily evaluate whether this scoring procedure may improve the over-
all discriminant value of the screening for the detection of PD-MCI or PD-D. Our data analysis
revealed that the new weighted MoCA total score with a cutoff score as proposed by the
authors of the test [11] which is widely used in clinical and research settings yields a higher sen-
sitivity than the original MoCA total score at a comparable specificity and that it is thus able to
better discriminate cognitively preserved from cognitively impaired PD patients. This result
was found both in the original dataset and the validation dataset. More precisely, in the original
data of study 1, the sensitivity of the MoCA increased substantially from 62.5 to 92% for the
detection of any cognitive disorder (PD-MCI or PD-D), while the specificity only slightly
decreased from 77.7 to 73%. Moreover, even in the independent sample of PD patients of study
2, the sensitivity of the MoCA increased from 68.8% to 81.3% while maintaining a specificity of
75%. This means that more cognitively impaired subjects were detected in both patient
Fig 3. MoCA original and weighted scores by diagnostic group in study 2.
doi:10.1371/journal.pone.0159318.g003
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samples, leading to a decreased number of false negatives. This can be explained by the fact
that the relatively easy items, for which the probability of a correct response is very high,
became less influential in the new weighting. Consequently, those patients that are indeed cog-
nitively impaired no longer receive numerous points for very easy items that lack a high diag-
nostic value. In fact, deficits in relevant domains are no longer “masked” or hidden within the
total score of the MoCA, so that cognitive dysfunction is more easily detected.
The sensitivity of the original MoCA score in our data (62.5% in study 1 and 68.8% in study
2) is remarkably low. Other studies found that the MoCA in its original form had a sensitivity
of 90% [13,14] for PD patients with cognitive impairment. However, a closer look to the study
by Hoops et al. [14] reveals that a cutoff score of 26/27 for cognitive impairment was used in
their sample of 132 PD patients. Thus, this cutoff is 1 point above the one in our study which
corresponds to the one that is proposed in the original test form and which is commonly used
in clinical practice. Importantly, when the cutoff score in our study 1 is raised by 1 point, we
also achieve a substantially higher sensitivity of 80.6% (which is in line with the result that the
AUC values in the two MoCA versions did not differ significantly as AUC values reflect sensi-
tivities and specificities of different cutoff scores). However, at the same time, specificity drops
down to 66.7% which approximates the even lower specificity of 53% reported by Hoops et al.
[14]. Although the primary goal of a screening test is to detect cognitive impairment, too many
false positives should be avoided. Rather, a good balance of sensitivity and specificity should be
pursued and is of great clinical use. This is especially important as in clinical practice, screening
tests are (unfortunately) often the only tool used—without further elaborate testing. With
regard to the sensitivity of 90% for the detection of PD-MCI and PD-D combined and the spec-
ificity of 75% reported by Dalrymple-Alford et al. [13], it has to be noted that their participants
were cognitively more impaired than the participants in our study: while the mean MoCA
score in the original, unweighted version was 23.2 ± 2.5 for PD-MCI and 16.9 ± 4.0 for PD-D
in their study, it was considerably higher in our study with values of 23.9 ± 3.2 for PD-MCI
and 22.45 ± 4.2 for PD-D. Thus, their deficits were naturally easier to detect. Although the
specificity of the MoCA with the weighted scoring system only decreased slightly from 77.7 to
73% in our study 1 (and even remained stable at 75% in study 2), this minor increase of
patients who did not suffer from cognitive dysfunction but were classified as cognitively
impaired should be commented on. In the new scoring algorithm, the comparably difficult
items have a stronger influence on the new total score. The result of this change is that if a
patient with preserved cognition (or more accurately: cognitive function with scores above the
defined cutoff score as tested in the elaborate neuropsychological test battery) failed one of
those more difficult subtests, he or she more easily scored below the cutoff score. The probabil-
ity that a patient fails a difficult item is naturally higher than for an easy item, and the impact is
higher in the weighted MoCA. As a consequence, the test loses specificity. However, as indi-
cated above, the main objective of a cognitive screening instrument is its sensitivity, i.e. to
detect affected individuals, while still showing an acceptable specificity. With a high sensitivity
of above 80% and a specificity of above 70% in both studies, we conclude that these criteria are
fulfilled with the new MoCA scoring scheme.
As expected, our data analysis showed that the subtests differ markedly in their individual
predictive values. With regard to the specific subtests which are weighted stronger in the new
MoCA scoring procedure on the basis of these predictive values, our results correspond largely
to findings concerning the typical cognitive deficits associated with PD. The alternating trail
making subtest as an executive task and the clock-drawing subtest as an executive and visuo-
spatial task were the subtests with the highest predictive value, followed by the cube copy,
again as a visuospatial task, verbal fluency, again an executive task, and the memory subtests
learning and memory. In line with these findings, executive functions are the functions that are
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most frequently impaired in the early stages of PD [38,39], with verbal fluency as a frequently
used and affected task [22], and visuoconstructive deficits are also common [40,41]. Further-
more, memory dysfunction is frequent [42,43]. The high weight that the subtests received
through the new weighting is thus meaningful. However, also the subtest repetition of sen-
tences has received a high weight. As this is a classified language task, this seems astonishing at
first sight. However, repetition of sentences strongly depends on working memory so that it
can be assumed that the reason why PD patients score low on this subtest is dysfunction in
working memory, rather than a primary language deficit. Working memory is usually concep-
tualized as an important subfunction of executive functions and, as stated above, executive defi-
cits are a hallmark of cognitive dysfunction in PD [44,45]. As attention is also a domain
frequently affected in PD, the fact that all three subtests which are assigned to the attention
domain in the MoCA (digit span, target tapping, serial subtraction) only receive a low weight is
unexpected. Remarkably, while only 10 out of our 25 PD patients with cognitive impairment in
study 1 failed one of the MoCA attention tests, 17 patients showed deficits on at least one atten-
tion test in the elaborate neuropsychological test battery (digit span forward, digit span back-
ward). One possible explanation for this discrepancy is that the MoCA subtests do not validly
measure the underlying construct of attention or at least are not sensitive enough. In fact, the
difficulty level of these tasks in the MoCA is low. For example, the digit span backwards only
requires the repetition of three numbers in reverse order which is comparably simple. This
aspect needs further investigation.
Interestingly, the three MoCA subtests that have been suggested to lack discriminatory
value in previous research including a PD sample [23] also receive the lowest weight in our sug-
gested scoring: the target tapping, the naming, and the orientation tasks. Finally, the two spe-
cific subtests with the highest predictive accuracy (alternating trail making and clock-drawing)
are also in line with previous studies examining the diagnostic accuracies of MoCA subtests in
a non-PD population [46,47]. This further supports our conclusions about the diagnostic util-
ity of the individual subtests and suggests that the proposed new scoring algorithm may also be
valuable to detect cognitive deficits in other patient groups. Finally, it should be noted that
despite the high accuracy of the alternating trail making task in the MoCA, the TMT of the
CERAD test battery did not differentiate between groups. Although speculative, one could
hypothesize that the criterion for correct or incorrect in the MoCA is a qualitative one based
on mistakes, whereas the TMT B/A index in the CERADmeasures the extra amount of time a
patient needs to accomplish the executive task B in comparison to the more simple version in
task A, and that the qualitative measure is more sensitive. A second possible explanation is that
the alternating trail making task is the first task that has to be accomplished in the MoCA so
that it might be especially difficult for the patients to adapt themselves to the task. Another
simple explanation that has to be taken into account is that the PD-D group was already slow
in part A of the TMT because of a generally slowed speed of processing and that the B/A Index
was thus given an unjustified high Z-score. However, these aspects need further research.
The present study is not the first one that recognized the necessity to compensate for some
weaknesses of the MoCA while at the same time attempting to preserve its strengths.
Koski, Xie, and Finch [48] administered the MoCA to 222 patients who scored at least 20
out of 30 on the MMSE and analyzed the data with a unidimensional Rasch model. They con-
cluded that many items in the MoCA (the orientation items city, place, year, and month, nam-
ing a lion and a camel, and the digit span forward) were found to be too easy for the population
for which it was intended and that therefore, many non-demented patients had to answer
“unnecessary” items for which the probability of a correct response is close to 100%. They sug-
gested that dropping easy items and constructing additional difficult items would improve the
precision of the scale for estimating cognitive ability in non-demented patients—the
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population for which it was originally designed. They further recommended that if the MoCA
is primarily used for patients with milder cognitive dysfunction, dropping the easier items may
have the potential to shorten the length of the test without losing any information. The
approach of the current study constitutes a practical and valuable alternative to the suggestion
of Koski et al. [48] in that it leaves the content of the subtests unchanged, while at the same
time decreasing the influence of items which might show a ceiling effect in patients which are
only mildly impaired. In another study, Koski, Xie, and Konsztowicz [49] demonstrated that a
more accurate estimate of cognitive ability may be achieved by combining information from
the MoCA and the MMSE. They suggested that adding information from the MMSE (three-
word repetition and recall, copy pentagons, repeat sentence, and write sentence) to the MoCA
would reduce measurement error by 13.8% and improve measurement of cognition in the
upper levels of ability. However, the algorithm they developed was only intended for quantita-
tive comparison of patients or tracking change over time and not for screening purposes.
Following the discussion about different cutoff scores in the section above, another
approach to improve the diagnostic accuracy of the MoCA attempted by some research groups
was to change the threshold for cognitive impairment. Larner [10] and Waldron-Perrine and
Axelrod [50] suggested a lower cutoff score (< 21/30) than that suggested by the authors of the
MoCA (< 26/30) [11]. Luis et al. [51] administered the MoCA to patients with AD, MCI, and
normal cognition and the results of their ROC analysis showed that a cutoff score of 23/30
might be superior. Damian et al. [46] empirically examined the threshold scores of the MoCA
and suggested that while the original cutoff of 26/30 may be optimal for screening in primary
care, a cutoff score of 24/30 would improve the predictive value of the MoCA in settings where
the probability of cognitive impairment is comparably high (20% prevalence of MCI or demen-
tia). The discussion concerning different cutoffs for the detection of cognitive impairment is
important, yet it does not solve the problem that the subtests that are especially relevant for the
detection of dysfunction receive an insufficient number of points and that their diagnostic
power should be exploited. On the contrary, lowering the cutoff score for cognitive impairment
could even exacerbate the problem in that the “easy” items with a high number of points would
have an even stronger influence on the classification of the cognitive state. This may result in
an increased number of false negatives which would ultimately lead to a decreased sensitivity
of the test.
Several limitations need to be considered when interpreting the findings of the current
study. First, the sample size, especially in study 2, was comparably small. This problem gener-
ally increases the probability that samples may be selected and non-representative. However,
despite this shortcoming, the results were broadly similar in both studies, so that the data sets
validate each other. Furthermore, the patients were recruited consecutively, possibly reducing
the probability of selectiveness. Nevertheless, further studies with larger patient samples are
urgently needed to confirm the higher diagnostic value of the new MoCA scoring algorithm. A
second limitation of the study concerns the method of weighting the subtests and the difference
of points in relation to the difference in AUCs. In order to achieve a meaningful solution con-
cerning the weighting, a mathematical operation was necessary in form of creating equally
sized groups based on the AUCs of the subtests, instead of directly deducing the points from
the AUCs. With a bigger sample size and thereby a possibly broader range of AUCs, this inter-
mediate step might prove unnecessary and could be omitted, and a more direct and precise
weight allocation might be achieved. This might even further enhance diagnostic accuracy of
the MoCA. Again, future studies might face this task. Furthermore, it has to be considered that
depression may have affected performance in the MoCA, as depression was not an exclusion
criterion in our patients. In fact, mean scores on the GDS-15 were above the cutoff of 4/5 points
on depressive symptoms [52] in the PD-D group in both samples. However, mean scores were
Improving the Diagnostic Utility of the MoCA
PLOSONE | DOI:10.1371/journal.pone.0159318 July 20, 2016 14 / 19
still relatively low with 7.7 and 5.9. Furthermore, as depression is very common among patients
with PD [53], and is related to severity of cognitive symptoms [54], this pattern was expected.
Most importantly, cognitive screening instruments are suitable to detect cognitive dysfunction,
but not to clarify the cause of cognitive symptoms or differentiate between primary cognitive
symptoms and deficits caused by depressive symptoms. Thus, depressive symptoms were not
considered in the development of the weighting procedure which was explicitly based on a typ-
ical sample of PD patients. A more general limitation is that the MoCA only offers one cutoff
score for “impaired” versus “not impaired” and different levels of impairment are neglected. As
we intended to keep the test as close to the original version as possible, we did not suggest addi-
tional cutoff scores for a more differentiated evaluation of cognitive functions and forwent a
ROC analysis for the different PD groups (PD-MCI and PD-D). However, it would be a valu-
able approach for future studies with large sample sizes of patients with different levels of cog-
nitive impairment. It should also be noted that there was a relatively large age range of PD
patients in both study 1 and 2 which was not controlled for, and that it cannot be ruled out that
age may have confounded the cognitive measures. However, both samples were consecutively
recruited clinical samples of PD patients, and it can thus be assumed that they represent a typi-
cal group of patients presenting in neurological settings. Finally, it should be mentioned that
alternative approaches to determine the relative importance and discriminating power of the
individual MoCA items exist, such as discriminant function analysis and logistic regression. It
would be valuable to use and compare one of the alternative approaches in further studies.
The results of our study suggest that weighting the MoCA subtests according to their respec-
tive diagnostic values may optimize diagnostic accuracy in the assessment of cognitive
impairment of PD patients. Further studies with larger samples sizes of PD patients to evaluate
the new scoring system are needed. One of the strengths of the proposed approach lies in
improving the detection of patients with milder forms of cognitive impairment, who are the
ideal target group for interventions aimed at preventing or slowing the onset of dementia.
Future interventions are in fact likely to yield the greatest benefit if initiated in an early phase,
when cognitive deficits are mild [55]. Next to pharmacological therapy, non-pharmacological
treatments to enhance cognition in PD or to prevent a further deterioration of functions of cog-
nitively impaired PD patients have attracted increasing interest with promising results e.g. for
cognitive training and physical exercise [56]. Precise evaluation of cognitive dysfunction and
its stabilization or enhancement induced by interventions is crucial, and a version of the
MoCA allowing a more precise scoring may contribute to that.
As already mentioned above, another strength of the approach adopted in the current study
is that, in contrast to other attempts at correcting the limitations of the MoCA by adding or
deleting subtests, the item compilation of this established instrument is not changed and that
only an additional scoring table is necessary. This has several advantages: No administrative
burden will be placed on clinicians and there is also no need for the clinician to acquire the
rules and instructions of an additional/new test. Since testing costs time and money, there is
also a potential reduction with regard to financial and time investment. In addition, it would be
possible to compare MoCA results to previous studies, because the raw values remain the
same. Furthermore, it would theoretically be possible to develop different weights and scoring
systems for different patient groups. More specifically, the same test could be used for different
patient groups and different scoring procedures could be applied. Finally, a more general
advantage is that the items of the MoCA were carefully chosen by the developers of the MoCA
[11] and only the scoring system is insufficiently elaborate.
On a final note, it should be said that even if an optimally weighted screening test is created
in this way, it is unlikely that it will ever approach the reliability and validity of a well-estab-
lished and psychometrically sound neuropsychological test battery. Nevertheless, screening
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procedures have high value as a time-economic, easy to use tool for a first step in detecting cog-
nitive impairment in clinical practice. For PD patients (and also patients with other clinical
conditions), they are embedded as a crucial element in the diagnostic process. More specifi-
cally, they serve Level I diagnosis of PD-MCI according to Litvan et al. [8] and Level I diagnosis
of PD-D according to Dubois et al. [57].
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